This CCRP Initiative grant supports the early-stage development of therapeutics designed to mitigate adverse health effects stemming from toxic chemical exposure. Chemical threats include compounds used in terrorist attacks or accidentally released from industrial sources, such as chemical warfare agents, toxic industrial chemicals, and pesticides. The grant’s scope involves validating therapeutic targets and conducting preclinical characterization of lead compounds. The UG3 phase focuses on initial target validation and lead compound characterization, progressing to the UH3 phase for candidate optimization and in vivo efficacy demonstration in relevant post-exposure models. The objective is to deliver at least one well-characterized therapeutic candidate by the funding period’s conclusion. This grant is for advancing essential medical countermeasures against a range of chemical threats.
Opportunity ID: 341905
General Information
| Document Type: | Grants Notice |
| Funding Opportunity Number: | PAR-22-209 |
| Funding Opportunity Title: | CCRP Initiative: Countermeasures Against Chemical Threats (CounterACT) Therapeutics Discovery and Early-Stage Development (UG3/UH3 Clinical Trial Not Allowed) |
| Opportunity Category: | Discretionary |
| Opportunity Category Explanation: | – |
| Funding Instrument Type: | Cooperative Agreement |
| Category of Funding Activity: | Education Environment Health |
| Category Explanation: | – |
| Expected Number of Awards: | – |
| Assistance Listings: | 93.113 — Environmental Health |
| Cost Sharing or Matching Requirement: | No |
| Version: | Synopsis 1 |
| Posted Date: | Jul 07, 2022 |
| Last Updated Date: | Jul 07, 2022 |
| Original Closing Date for Applications: | Oct 17, 2024 |
| Current Closing Date for Applications: | Oct 17, 2024 |
| Archive Date: | Nov 22, 2024 |
| Estimated Total Program Funding: | – |
| Award Ceiling: | $350,000 |
| Award Floor: | – |
Eligibility
| Eligible Applicants: | Special district governments Others (see text field entitled “Additional Information on Eligibility” for clarification) State governments Private institutions of higher education City or township governments Independent school districts Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education County governments Public housing authorities/Indian housing authorities Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses Native American tribal organizations (other than Federally recognized tribal governments) Public and State controlled institutions of higher education Native American tribal governments (Federally recognized) Small businesses |
| Additional Information on Eligibility: | Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession; Non-domestic (non-U.S.) Entities (Foreign Institutions) are not eligible to apply. Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement, are allowed. |
Additional Information
| Agency Name: | National Institutes of Health |
| Description: | This Funding Opportunity Announcement (FOA) solicits applications for the early-stage development of therapeutics to mitigate the adverse health effects resulting from toxic chemical exposure. Chemical threats are toxic compounds that could be used in a terrorist attack or accidentally released from industrial production, storage or shipping. They include specific chemical warfare agents, toxic industrial chemicals, pesticides, and pharmaceutical-based agents. The overall scope of this solicitation includes validation of therapeutic targets and preclinical characterization of lead compounds. The UG3 phase of this FOA supports target validation and characterization of initial lead compound(s); UH3 phase activities include candidate optimization and in vivo demonstration of activity and efficacy in relevant post-exposure models. At the conclusion of the overall UG3/UH3 funding period, projects are expected to deliver at least one well-characterized therapeutic candidate. |
| Link to Additional Information: | http://grants.nih.gov/grants/guide/pa-files/PAR-22-209.html |
| Grantor Contact Information: | If you have difficulty accessing the full announcement electronically, please contact:
NIH OER Webmaster
OERWebmaster03@od.nih.gov Email:OERWebmaster03@od.nih.gov |
Version History
| Version | Modification Description | Updated Date |
|---|---|---|
Related Documents
Folder 341905 Full Announcement-PAR-22-209 -> PAR-22-209-Full-Announcement.pdf
Packages
| Agency Contact Information: | NIH OER Webmaster OERWebmaster03@od.nih.gov Email: OERWebmaster03@od.nih.gov |
| Who Can Apply: | Organization Applicants |
| Assistance Listing Number | Competition ID | Competition Title | Opportunity Package ID | Opening Date | Closing Date | Actions |
|---|---|---|---|---|---|---|
| FORMS-G | Use for due dates on or before January 24, 2023 | PKG00275505 | Sep 17, 2022 | Jan 24, 2023 | View | |
| FORMS-H | Use for due dates on or after January 25, 2023 | PKG00278453 | Nov 15, 2022 | Oct 17, 2024 | View |
Package 1
Mandatory forms
341905 RR_SF424_5_0-5.0.pdf
341905 PHS398_CoverPageSupplement_5_0-5.0.pdf
341905 RR_OtherProjectInfo_1_4-1.4.pdf
341905 PerformanceSite_4_0-4.0.pdf
341905 RR_KeyPersonExpanded_4_0-4.0.pdf
341905 RR_Budget_3_0-3.0.pdf
341905 PHS398_ResearchPlan_4_0-4.0.pdf
341905 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
341905 RR_SubawardBudget30_3_0-3.0.pdf
341905 PHS_AssignmentRequestForm_3_0-3.0.pdf
Package 2
Mandatory forms
341905 RR_SF424_5_0-5.0.pdf
341905 PHS398_CoverPageSupplement_5_0-5.0.pdf
341905 RR_OtherProjectInfo_1_4-1.4.pdf
341905 PerformanceSite_4_0-4.0.pdf
341905 RR_KeyPersonExpanded_4_0-4.0.pdf
341905 RR_Budget_3_0-3.0.pdf
341905 PHS398_ResearchPlan_5_0-5.0.pdf
341905 PHSHumanSubjectsAndClinicalTrialsInfo_3_0-3.0.pdf
Optional forms
341905 RR_SubawardBudget30_3_0-3.0.pdf
341905 PHS_AssignmentRequestForm_3_0-3.0.pdf
Share This Post, Choose Your Platform!
About the Author: osnqt
